Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate Plaque Psoriasis”

619 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 619 results

Not applicableNot Yet RecruitingNCT06802848
What this trial is testing

Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

Who this might be right for
Plaque PsoriasisPsoriatic ArthritisScalp Psoriasis+3 more
Chongqing Genrix Biopharmaceutical Co., Ltd 1,000
Large-scale testing (Phase 3)Study completedNCT06088043
What this trial is testing

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Who this might be right for
Plaque Psoriasis
Takeda 693
Early research (Phase 1)Study completedNCT07051538
What this trial is testing

A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
Guangdong Hengrui Pharmaceutical Co., Ltd 64
Large-scale testing (Phase 3)Study completedNCT01891864
What this trial is testing

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

Who this might be right for
Chronic Stable Plaque Psoriasis
Sandoz 531
Large-scale testing (Phase 3)Study completedNCT02513550
What this trial is testing

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Eli Lilly and Company 1,257
Testing effectiveness (Phase 2)Study completedNCT03230292
What this trial is testing

Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
UCB Biopharma SRL 43
Testing effectiveness (Phase 2)Study completedNCT03069144
What this trial is testing

Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Who this might be right for
PsoriasisPsoriasis Vulgaris
Haus Bioceuticals 28
Large-scale testing (Phase 3)Study completedNCT04967508
What this trial is testing

Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Who this might be right for
PsoriasisModerate to Severe Plaque Psoriasis
Samsung Bioepis Co., Ltd. 503
Testing effectiveness (Phase 2)Study completedNCT00585650
What this trial is testing

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Who this might be right for
Psoriasis
University of California, Irvine 20
Not applicableStudy completedNCT05650060
What this trial is testing

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Novartis Pharmaceuticals 163
Testing effectiveness (Phase 2)Study completedNCT01710046
What this trial is testing

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Pfizer 12
Large-scale testing (Phase 3)Study completedNCT00338143
What this trial is testing

Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies

Who this might be right for
Psoriasis
Genentech, Inc. 1,200
Not applicableActive Not RecruitingNCT06247319
What this trial is testing

Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece

Who this might be right for
Moderate Plaque PsoriasisModerate PsoriasisPsoriasis
AbbVie 250
Large-scale testing (Phase 3)Study completedNCT01194219
What this trial is testing

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Amgen 844
Not applicableStudy completedNCT04428411
What this trial is testing

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Who this might be right for
Plaque Psoriasis
Pfizer 486
Post-approval studies (Phase 4)Study completedNCT00168753
What this trial is testing

Community Based Trial for AMEVIVE®

Who this might be right for
Moderate to Severe Chronic Plaque Psoriasis
Astellas Pharma Inc 114
Post-approval studies (Phase 4)Study completedNCT03440736
What this trial is testing

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

Who this might be right for
PsoriasisMetabolic Syndrome
Novartis Pharmaceuticals 781
Large-scale testing (Phase 3)Study completedNCT05120297
What this trial is testing

Efficacy and Safety of AK101 in Subjects With Psoriasis

Who this might be right for
Psoriasis Vulgaris
Akeso 452
Testing effectiveness (Phase 2)Study completedNCT01208090
What this trial is testing

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
Actelion 326
Large-scale testing (Phase 3)Study completedNCT02474082
What this trial is testing

Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Who this might be right for
Psoriasis
Novartis Pharmaceuticals 202
Next Page